Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape

Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape

In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future perspective for oral SERDs in ER+/HER2- advanced or metastatic breast cancer.

Dr.Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr.Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai explore new endocrine therapies for ER+/HER2- advanced or metastatic breast cancer. More specifically, they discuss oral SERDs efficacy and safety profile as well as their place in treatment landscape

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(90)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mars 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Dec 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Nov 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Maj 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Maj 202520min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Apr 202521min

Populärt inom Utbildning

historiepodden-se
rss-bara-en-till-om-missbruk-medberoende-2
det-skaver
nu-blir-det-historia
harrisons-dramatiska-historia
sektledare
not-fanny-anymore
rss-viktmedicinpodden
johannes-hansen-podcast
roda-vita-rosen
allt-du-velat-veta
kan-jag-sa-kan-du-podden
i-vantan-pa-katastrofen
rikatillsammans-om-privatekonomi-rikedom-i-livet
sa-in-i-sjalen
rss-max-tant-med-max-villman
rss-foraldramotet-bring-lagercrantz
rss-ar-det-rimligt
rss-autismandan
rss-i-skenet-av-blaljus